Drug intelligence / Profile preview

TLR4-IN-C34

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral, Intraperitoneal, Intraventricular

Overview

TLR4-IN-C34 is a small molecule drug that functions as a potent and selective antagonist of Toll-like receptor 4 (TLR4). It is a 2-acetamidopyranoside that inhibits TLR4 signaling in enterocytes and macrophages. By blocking TLR4, it attenuates TLR4-mediated cytokine release and exhibits anti-inflammatory effects. It has been studied in animal models for conditions like endotoxemia and necrotizing enterocolitis, where it reduces systemic inflammation and decreases the expression of inflammatory markers like TNFα and iNOS.

Other names: 1-methylethyl 2-(acetylamino)-2-deoxy-α-D-glucopyranoside, 3,4,6-triacetate

Targets

TLR4 (Toll-like receptor 4)

Beyond the preview

Go deeper on TLR4-IN-C34.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TLR4-IN-C34.

Explore the full profile